清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

恩帕吉菲 达帕格列嗪 医学 卡格列净 危险系数 内科学 置信区间 心力衰竭 糖尿病 倾向得分匹配 2型糖尿病 相对风险 内分泌学
作者
Mikhail Kosiborod,Carolyn S.P. Lam,Shun Kohsaka,Dae Jung Kim,Avraham Karasik,Jonathan E. Shaw,Navdeep Tangri,Su-Yen Goh,Marcus Thuresson,Hungta Chen,Filip Surmont,Niklas Hammar,Peter Fenici
出处
期刊:Journal of the American College of Cardiology [Elsevier]
卷期号:71 (23): 2628-2639 被引量:351
标识
DOI:10.1016/j.jacc.2018.03.009
摘要

Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with a broader risk profile, but these studies focused on heart failure and death and were limited to the United States and Europe.The purpose of this study was to examine a broad range of CV outcomes in patients initiated on SGLT-2i versus other glucose-lowering drugs (oGLDs) across 6 countries in the Asia Pacific, the Middle East, and North American regions.New users of SGLT-2i and oGLDs were identified via claims, medical records, and national registries in South Korea, Japan, Singapore, Israel, Australia, and Canada. Propensity scores for SGLT-2i initiation were developed in each country, with 1:1 matching. Hazard ratios (HRs) for death, hospitalization for heart failure (HHF), death or HHF, MI, and stroke were assessed by country and pooled using weighted meta-analysis.After propensity-matching, there were 235,064 episodes of treatment initiation in each group; ∼27% had established CV disease. Patient characteristics were well-balanced between groups. Dapagliflozin, empagliflozin, ipragliflozin, canagliflozin, tofogliflozin, and luseogliflozin accounted for 75%, 9%, 8%, 4%, 3%, and 1% of exposure time in the SGLT-2i group, respectively. Use of SGLT-2i versus oGLDs was associated with a lower risk of death (HR: 0.51; 95% confidence interval [CI]: 0.37 to 0.70; p < 0.001), HHF (HR: 0.64; 95% CI: 0.50 to 0.82; p = 0.001), death or HHF (HR: 0.60; 95% CI: 0.47 to 0.76; p < 0.001), MI (HR: 0.81; 95% CI: 0.74 to 0.88; p < 0.001), and stroke (HR: 0.68; 95% CI: 0.55 to 0.84; p < 0.001). Results were directionally consistent across both countries and patient subgroups, including those with and without CV disease.In this large, international study of patients with T2D from the Asia Pacific, the Middle East, and North America, initiation of SGLT-2i was associated with a lower risk of CV events across a broad range of outcomes and patient characteristics. (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors [CVD-REAL]; NCT02993614).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fengfenghao完成签到 ,获得积分10
7秒前
energyharvester完成签到 ,获得积分10
43秒前
1分钟前
大脸猫发布了新的文献求助10
1分钟前
1分钟前
研友_8y2G0L完成签到,获得积分10
1分钟前
一叶扁舟完成签到 ,获得积分10
1分钟前
Akim应助科研通管家采纳,获得10
1分钟前
1分钟前
大脸猫完成签到 ,获得积分10
1分钟前
1分钟前
3分钟前
狂野乌冬面完成签到 ,获得积分10
3分钟前
GCL发布了新的文献求助10
3分钟前
cindy完成签到,获得积分10
4分钟前
4分钟前
4分钟前
科研通AI2S应助GCL采纳,获得10
5分钟前
上官凯凯完成签到 ,获得积分10
6分钟前
Ava应助breeze采纳,获得10
6分钟前
benoit完成签到,获得积分10
6分钟前
7分钟前
fff发布了新的文献求助10
7分钟前
传奇完成签到 ,获得积分10
7分钟前
8分钟前
9分钟前
Jack80发布了新的文献求助10
9分钟前
gszy1975完成签到,获得积分10
10分钟前
RicH完成签到 ,获得积分10
10分钟前
10分钟前
蝴蝶完成签到 ,获得积分10
10分钟前
kbcbwb2002完成签到,获得积分10
11分钟前
传奇3应助Neverlocked采纳,获得10
11分钟前
陈东生发布了新的文献求助10
11分钟前
CipherSage应助陈东生采纳,获得30
11分钟前
tufei完成签到,获得积分10
12分钟前
13分钟前
虞鱼瑜发布了新的文献求助10
13分钟前
Ally应助虞鱼瑜采纳,获得10
13分钟前
所所应助科研通管家采纳,获得10
13分钟前
高分求助中
Sustainability in Tides Chemistry 1500
Handbook of the Mammals of the World – Volume 3: Primates 805
拟南芥模式识别受体参与调控抗病蛋白介导的ETI免疫反应的机制研究 550
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Manual of Sewer Condition Classification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3068129
求助须知:如何正确求助?哪些是违规求助? 2722142
关于积分的说明 7476048
捐赠科研通 2369115
什么是DOI,文献DOI怎么找? 1256205
科研通“疑难数据库(出版商)”最低求助积分说明 609490
版权声明 596826